What do systematic reviews say?

Antacids vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antacids vs placebo or no prophylaxis

Antacids showed no clear difference in number of participants requiring blood transfusions compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.3, 2.96]
  2 studies · 226 participants
  Low

Antacids vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo or no prophylaxis

Sucralfate probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.53 [0.32, 0.88]
  7 studies · 598 participants
  Moderate

Sucralfate vs placebo or no prophylaxis

Sucralfate showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 1.33 [0.86, 2.04]
  4 studies · 450 participants
  Low

Sucralfate vs placebo or no prophylaxis

Sucralfate showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.97 [0.66, 1.43]
  5 studies · 500 participants
  Low

Sucralfate vs placebo or no prophylaxis

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 224 participants
  Low

Sucralfate vs placebo or no prophylaxis

Sucralfate showed no clear difference in number of participants requiring blood transfusion compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.6 [0.15, 2.44]
  1 study · 200 participants
  Low

Interventions vs placebo or no prophylaxis

Interventions showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 1.1 [0.9, 1.34]
  19 studies · 2159 participants
  Low

Sucralfate vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions vs placebo or no prophylaxis

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 447 participants
  Low

Interventions vs placebo or no prophylaxis

Interventions probably leads to lower number of participants requiring blood transfusion compared with placebo or no prophylaxis (moderate certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.41, 0.97]
  9 studies · 981 participants
  Moderate

Interventions vs placebo or no prophylaxis

The review found no eligible studies for this question.

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

H2 receptor antagonists vs placebo or no prophylaxis

H2 receptor antagonists probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 0.5 [0.36, 0.7]
  24 studies · 2149 participants
  Moderate

H2 receptor antagonists vs placebo or no prophylaxis

H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 1.12 [0.85, 1.48]
  8 studies · 945 participants
  Low

H2 receptor antagonists vs placebo or no prophylaxis

H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).

• Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units 2018 · Cochrane Headline outcomes only
  RR 1.12 [0.88, 1.42]
  14 studies · 1428 participants
  Low

Prokinetic vs placebo

It is very uncertain whether prokinetic changes not symptom‐free or no symptom improvement compared with placebo (very low certainty).

• Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only
  RR 0.81 [0.74, 0.89]
  29 studies · 10044 participants
  Very low

Prokinetic vs placebo

• Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 2914 participants
  Low

Prokinetic vs placebo

• Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1822 participants
  Very low

Prokinetic vs placebo

• Prokinetics for functional dyspepsia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1774 participants
  Very low